Artelo Biosciences Announces Data From Preclinical Trial In Neuropathic Pain From Spinal Cord Injury Shows Lowered Mechanical Hypersensitivi

Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced positive new data from a preclinical study in neuropathic pain from spinal cord injury. The findings are being presented today at the International Cannabinoid Research Society 2026 Annual Symposium in Dijon, France and the Company believes the results support the broad therapeutic potential of ART26.12, Artelo’s proprietary clinical stage selective fatty acid binding protein 5 (FABP5) inhibitor, currently progressing in Phase 1 development. Results demonstrated that selective FABP5 inhibition: Reduced mechanical hypersensitivity associated with nerve injury Decreased Spontaneous Pain-related Behaviors Suppressed noc...